The developer behind Final Fantasy XVI teams up with luxury watchmaker Franck Muller to create a limited watch collection ...

Eikon Therapeutics, a company headed by the former Merck executive who steered the cancer drug Keytruda to FDA approval, has raised $350.7 million to support a pipeline that includes a lead drug ...

The upward trajectory continues for Eikon Therapeutics, which announced that it has raised $351 million to fund various cancer related clinical trials. The Series D funding unveiled Wednesday morning ...

Eikon Therapeutics is no stranger to eye-popping funding rounds, and the cancer-focused biotech has continued this trend with a $350.7 million series D to fuel its various clinical trials.

To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Eikon Therapeutics, a well-funded drug startup run by Merck & Co.’s former research chief, has raised ...

Startup Eikon Therapeutics raised one of the biggest biotech rounds thus far in this young year. The Hayward, California-based drug startup closed on nearly $351 million in a Series D from the ...

HAYWARD, Calif., February 26, 2025--(BUSINESS WIRE)--Eikon Therapeutics, Inc., a pivotal-stage biotechnology company that integrates advanced engineering with cutting-edge molecular and cell ...

The funding, led by existing and new investors, is expected to support Eikon’s efforts to integrate advanced computing, automation, and data science that drives innovation in drug development. Eikon ...